NCT05878314View on ClinicalTrials.gov

Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer

RecruitingOBSERVATIONAL
Enrollment

504

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2035

Conditions
Hormone Receptor Positive HER-2 Negative Breast Cancer
Trial Locations (1)

72076

RECRUITING

Department of Women's Health, Tübingen

All Listed Sponsors
collaborator

University Hospital Ulm

OTHER

collaborator

University Hospital Freiburg

OTHER

lead

University Hospital Tuebingen

OTHER